Results 161 to 170 of about 681,792 (231)

FGFR Inhibitor AZD4547 [PDF]

, 2020
openaire   +1 more source

FGFR pathway genomic aberrations and response to FGFRs inhibitors

Annals of Oncology, 2017
M. Faure, A. Hollebecque, R. Bahleda, J-C. Soria, V. Dyevre   +4 more
openaire   +1 more source

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. [PDF]

Mol Cancer Ther, 2020
Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S.   +17 more
europepmc   +1 more source

Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models. [PDF]

Cancer Med
Afshan S, Kim YG, Mattsson J, Åkerfelt M, Härkönen P, Baumgartner M, Nees M.   +6 more
europepmc   +1 more source

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. [PDF]

Clin Cancer Res
Wu Q, Ellis H, Siravegna G, Michel AG, Norden BL, Fece de la Cruz F, Balasooriya ER, Zhen Y, Silveira VS, Che J, Corcoran RB, Bardeesy N.   +11 more
europepmc   +1 more source

Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider. [PDF]

J Adv Pract Oncol
Schwartz G, Darling JO.
europepmc   +1 more source

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. [PDF]

J Hepatol
DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F.   +16 more
europepmc   +1 more source

Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors. [PDF]

Transl Lung Cancer Res
Kitai H, Ebi H.
europepmc   +1 more source

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. [PDF]

Int J Mol Sci, 2020
Lima NC, Atkinson E, Bunney TD, Katan M, Huang PH.   +4 more
europepmc   +1 more source

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors. [PDF]

Biomed Res Int, 2020
Li Y, Wu L, Tao W, Wu D, Ma F, Li N.
europepmc   +1 more source